Nascent Biotech (NBIO) Stock Statistics & Valuation Metrics
Total Valuation
Nascent Biotech has a market cap or net worth of $34.57K. The enterprise value is -$197.96B.
- Market Cap
- $34.57K
- Enterprise Value
- -$197.96B
Share Statistics
Nascent Biotech has 172,842,670 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 172,842,670
- Owned by Insiders
- ―
- Owned by Institutions
- 0.06%
Financial Efficiency
Nascent Biotech’s return on equity (ROE) is 8.13 and return on invested capital (ROIC) is 1662.02%.
- Return on Equity (ROE)
- 8.13
- Return on Assets (ROA)
- -3.78
- Return on Invested Capital (ROIC)
- 1662.02%
- Return on Capital Employed (ROCE)
- 8.69
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.04M
- Employee Count
- 2
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Nascent Biotech is -0.01. Nascent Biotech’s PEG ratio is -0.00.
- PE Ratio
- -0.01
- PS Ratio
- 0.00
- PB Ratio
- -0.12
- Price to FCF
- -0.03
- Price to Operating Cash Flow
- -0.03
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Nascent Biotech had revenue of 0 and earned -2.09M in profits. Earnings per share was -0.01.
- Revenue
- 0
- Gross Profit
- -320.00K
- Operating Income
- -2.23M
- Pretax Income
- -2.09M
- Net Income
- -2.09M
- EBITDA
- 527.88K
- Earnings Per Share (EPS)
- -0.01
Cash Flow
In the last 12 months, operating cash flow was -1.35M and capital expenditures -2, giving a free cash flow of -1.35M billion.
- Operating Cash Flow
- -1.35M
- Free Cash Flow
- -1.35M
- Free Cash Flow per Share
- -0.01
Dividends & Yields
Nascent Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -3443.56%
- Earnings Yield
- -6703.31%
Stock Price Statistics
- Beta
- 61.94
- 52-Week Price Change
- 740.00%
- 50-Day Moving Average
- 0.08
- 200-Day Moving Average
- 0.08
- Relative Strength Index (RSI)
- ―
- Average Volume (3m)
- ―
Financial Position
Nascent Biotech as a current ratio of 0.68, with Debt / Equity ratio of -47.73%
- Current Ratio
- 0.68
- Quick Ratio
- 0.68
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- -0.47
- Interest Coverage Ratio
- -5.79
Taxes
In the past 12 months, Nascent Biotech has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Nascent Biotech EV to EBITDA ratio is -0.41, with an EV/FCF ratio of 0.18.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.41
- EV to Free Cash Flow
- 0.18
- EV to Operating Cash Flow
- 0.18
Balance Sheet
Nascent Biotech has $47.39K in cash and marketable securities with $59.00K in debt, giving a net cash position of -$11.61K billion.
- Cash & Marketable Securities
- $47.39K
- Total Debt
- $59.00K
- Net Cash
- -$11.61K
- Net Cash Per Share
- $0.00
- Tangible Book Value Per Share
- $0.00
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Nascent Biotech is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- 0
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
